Amitriptyline strenghtens effects of melphalan and bortezomib treatment by inhibiting acid sphingomyelinase

Onderzoeksoutput: Poster



Multiple myeloma (MM) is a haematological cancer characterized by the accumulation of monoclonal plasma cells in the bone marrow. Despite new advancements, MM remains incurable due to drug resistance. Malignant cells can adapt their lipid metabolism to attain higher rates of proliferation and avoid chemotherapy-induced apoptosis. In this study, we aimed (1) to identify changes in lipid metabolism in MM patients, (2) to investigate this altered metabolism in vitro.

Material and methods

A lipidomics assay was performed on plasma samples of MM patients and healthy controls. Effects of sphingomyelin and ceramide were evaluated on proliferation of human MM cell lines OPM2, U266, JJN3 and LP1. After treatment with standard-of-care (SoC) drugs melphalan and bortezomib, acid sphingomyelinase (ASM) content was measured on JJN3-derived exosomes by western blot. Exosomes were isolated by centrifugation, while exosome secretion was measured by nanoparticle tracking. Amitriptyline was used as an ASM inhibitor. Effects on apoptosis were measured by flow cytometry and western blot. To prove statistical significance, a Mann-Whitney U test was performed.


Lipidomics analysis revealed an upregulation of ceramides and downregulation of sphingomyelin in MM patients, leading to the conclusion that ASM, which transforms sphingomyelin into ceramide, is upregulated in MM patients. We confirmed this on bone marrow samples, comparing CD138+ to CD138- fractions. Addition of ceramide to MM cells increased viability, while sphingomyelin caused a decrease. ASM content was also increased in SoC-treated JJN3-derived exosomes. Furthermore, SoC drugs stimulated exosome secretion. Interestingly, amitriptyline (= ASM inhibitor, often prescribed in MM patients for neuropathic pain) increased the efficacy of both drugs on cell lines by activating PARP and caspase 3 pathways. Combination therapy was also successfully tested on primary MM samples.


SoC drugs increase ASM in primary MM cells, cell lines and their exosomes. Amitriptyline-based inhibition of ASM increases drug efficacy.
Originele taal-2English
Aantal pagina's205
StatusPublished - 25 jun 2019
EvenementMosa conference 2019: This time it’s personal: personalization as a solution in healthcare, medicine and research. - Maastricht, Netherlands
Duur: 25 jun 201926 sep 2019


ConferenceMosa conference 2019


Duik in de onderzoeksthema's van 'Amitriptyline strenghtens effects of melphalan and bortezomib treatment by inhibiting acid sphingomyelinase'. Samen vormen ze een unieke vingerafdruk.

Citeer dit